Cardiology overview electrophysiology: Difference between revisions

Jump to navigation Jump to search
Line 16: Line 16:
===Anticoagulation===
===Anticoagulation===
* Patients with a [[CHADS2 score]] of two or higher should be anticoagulated with [[warfarin]].  Some clinicians believe that any patient with [[congestive heart failure]] should also be anticoagulated with [[warfarin]].
* Patients with a [[CHADS2 score]] of two or higher should be anticoagulated with [[warfarin]].  Some clinicians believe that any patient with [[congestive heart failure]] should also be anticoagulated with [[warfarin]].
=Anticoagulation based on the CHADS<sub>2</sub> score ==
The following treatment strategies are recommended in the table below entitled Anticoagulation based on the CHADS2 score:<ref name="pmid15477396 " /><ref name=Gage2001 />
{| class="wikitable" style = "float: right; margin-left:15px; text-align:center"
|-
! Score
! Risk
! Anticoagulation Therapy
! Considerations
|-
| '''0'''
| Low
| [[Aspirin]]
| Aspirin daily
|-
| '''1'''
| Moderate
| Aspirin or Warfarin
| Aspirin daily or [[International normalized ratio|INR]] to 2.0-3.0, depending on factors such as patient preference
|-
| '''2 or greater'''
| Moderate or High
| [[Warfarin]]
| [[International normalized ratio|INR]] to 2.0-3.0, unless contraindicated (e.g. clinically significant GI bleeding, inability to obtain regular INR screening)
|}


===Rate Control vs Rhythm Control===
===Rate Control vs Rhythm Control===

Revision as of 20:32, 31 October 2011

Cardiology Overview

Home

Acute Coronary Syndromes

Antiplatelets and antithrombins

Cardiomyopathy

Congenital heart disease

Electrophysiology

Heart failure

Hypertension

Imaging

Invasive cardiology

Pericardial disease

Peripheral arterial disease

Pharmacology

Pregnancy

Preoperative evaluation

Prevention

Pulmonary hypertension

Stable angina

Valvular heart disease

Venous thromboembolism

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Brugada syndrome

STEMI and Arrhythmias

Implantable Cardiac Defibrillator

  • Should not be implanted within 40 days of STEMI
  • A patient should wear a defibrillator vest while awaiting AICD implantation
  • Amiodarone improves CV survival but not all cause survival in patients with an LVEF of <40%

Atrial Fibrillation

Cardioversion

  • In a patient with new onset atrial fibrillation, an attempt at cardioversion should be made. The patient should be anticoagulated with Coumadin for three weeks before the cardioversion and four weeks after the cardioversion. The anticoagulation after the cardioversion is due to the electrical mechanical dissociation that occurs in these patients.

Anticoagulation

Anticoagulation based on the CHADS2 score =

The following treatment strategies are recommended in the table below entitled Anticoagulation based on the CHADS2 score:[1][2]

Score Risk Anticoagulation Therapy Considerations
0 Low Aspirin Aspirin daily
1 Moderate Aspirin or Warfarin Aspirin daily or INR to 2.0-3.0, depending on factors such as patient preference
2 or greater Moderate or High Warfarin INR to 2.0-3.0, unless contraindicated (e.g. clinically significant GI bleeding, inability to obtain regular INR screening)

Rate Control vs Rhythm Control

  • Rhythm control offers no benefit over rate control in survival
  • Rate control is very important in preventing the tachycardia cardiomyopathy syndrome
  • Dronedarone reduces hospitalization for atrial fibrillation by about a quarter

Radiofrequency Ablation

  • A complication of radio frequency ablation is left atrial tachycardia or flutter. This complication may itself require treatment.
  • Anticoagulation should be continued after radiofrequency ablation.
  • In patients who have a rapid ventricular response rate in atrial fibrillation and who develop a tachycardia induced cardiomyopathy, AV junctional ablation can be undertaken with permanent pacemaker placement.

References

Template:WS Template:WH